It was only a matter of time before a re-rate of BDX, hugely...

It was only a matter of time before a re-rate of BDX, hugely overlooked by market. Jane Shaw
has been working on this test for 10+ years. The way they are talking about launch in the Webinars I feel NATA will be a formality.

Hearing the surgeon from Peter Mac talking so enthusiastically about this test and his comparison to the simplicity of a Cholesterol test is very encouraging. 42% of eligible women do not get screened by Mam's. Game changer in early diagnosis.

I took the IPO to directly fund this tests development, have taken more on market at lows and will take more to again when they raise to directly fund its launch later this year. Hopefully when they do raise it will be an entitlement offer to existing holders for those who cant get in the soph raise.

Huge cost saving to Govts healthcare especially in more mature women when mam's are more frequent. You just dont have these collection partners only to be knocked back by NATA.

Good luck all